Non-Alcoholic Fatty Liver Disease (NAFLD) is increasing in proportion to rise in obesity. Now it has become the most common cause of chronic liver disease after hepatitis B, hepatitis C and alcohol. It can be classified into simple fatty liver disease (or Non Alcoholic Fatty Liver, NAFL) and Non Alcoholic Steatohepatitis (NASH). The former has a benign prognosis but latter is associated with fibrosis and progression to cirrhosis. In early stage, fat accumulates within hepatocytes whereas at the same time the process of lipids removal by oxidation or export can’t keep pace with its biosynthesis.

The symptoms of both the settings are identical. They occur at any age and in children usually after 10 years. The most common symptoms are fatigue and discomfort in abdomen while patients who are obese with BMI > 25 about 1/3 have metabolic syndromes. Hepatomegaly may be present, although the signs of chronic liver disease are uncommon. Although its incidence is about 3% of population but it has come to our clinical observation that apart from obese patients, normal patients also have fatty liver on USG.

Keeping above facts in mind the present pilot study was conducted on the outdoor patients who attended the Moalejat and Modern Medicine OPD of Ajmal Khan Tibbiya College Hospital, Aligarh Muslim University, Aligarh. As there is no drug, so far, unequivocally proved to be effective in the prevention or regression of fatty liver, therefore, we opted the non pharmacopoeial preparation of Unani drugs to see its effect on established cases of NAFLD and only one type i.e NAFL was studied. There was no significant USG improvement by our drug formulation, yet clinical improvement was seen and was found to be significant to a great extent.